Article
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
EBioMedicine - 1 May 2018
Duchmann Matthieu, Yalniz Fevzi F, Sanna Alessandro, Sallman David, Coombs Catherine C, Renneville Aline, Kosmider Olivier, Braun Thorsten, Platzbecker Uwe, Willems Lise, Adès Lionel, Fontenay Michaela, Rampal Raajit, Padron Eric, Droin Nathalie, Preudhomme Claude, Santini Valeria, Patnaik Mrinal M, Fenaux Pierre, Solary Eric, Itzykson Raphael
Abstract excerpt
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.